Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 2
2005 1
2009 1
2010 1
2011 2
2012 2
2013 4
2014 1
2015 1
2016 2
2017 3
2018 8
2019 20
2020 11
2021 10
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Results by year

Filters applied: . Clear all
The following term was ignored: %
The following term was not found in PubMed: 20Loguercio
Page 1
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK; CARMELINA Investigators. Rosenstock J, et al. JAMA. 2019 Jan 1;321(1):69-79. doi: 10.1001/jama.2018.18269. JAMA. 2019. PMID: 30418475 Free PMC article. Clinical Trial.
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, Toto RD, Wanner C, Espeland MA, Mattheus M, Schnaidt S, Perkovic V, Gollop ND, McGuire DK. Marx N, et al. JAMA Cardiol. 2024 Feb 1;9(2):134-143. doi: 10.1001/jamacardio.2023.4602. JAMA Cardiol. 2024. PMID: 38170502 Free PMC article.
The findings from the CARMELINA trial suggest that both hypoglycemia and CV events more likely identify patients at high risk for both. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01897532 (CARMELINA) and NCT01243424 (CAROLINA)....
The findings from the CARMELINA trial suggest that both hypoglycemia and CV events more likely identify patients at high risk for bot …
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Hanssen NM, Jandeleit-Dahm KA. Hanssen NM, et al. Diab Vasc Dis Res. 2019 Jul;16(4):303-309. doi: 10.1177/1479164119842339. Epub 2019 Apr 24. Diab Vasc Dis Res. 2019. PMID: 31018682 Free PMC article. Review.
Linagliptin is the latest dipeptidyl peptidase-4 inhibitor evaluated in the CARMELINA trial. CARMELINA included individuals with type 2 diabetes and high cardiovascular and renal risk. ...Although numerically low, CARMELINA did confirm increased rates of panc …
Linagliptin is the latest dipeptidyl peptidase-4 inhibitor evaluated in the CARMELINA trial. CARMELINA included individuals wi …
CARMELINA: An important piece of the DPP-4 inhibitor CVOT puzzle.
Schernthaner G, Wanner C, Jurišić-Eržen D, Guja C, Gumprecht J, Jarek-Martynowa IR, Karasik A, Lalić N, Mankovsky BN, Prázný M, Tankova T, Tsur A, Wascher TC, Wittmann I. Schernthaner G, et al. Diabetes Res Clin Pract. 2019 Jul;153:30-40. doi: 10.1016/j.diabres.2019.05.013. Epub 2019 May 20. Diabetes Res Clin Pract. 2019. PMID: 31121272 Free article.
To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group of diabetes specialists from the Central and Eastern Europe region to discuss the new disclosures. ...Here, we noted the clinical relevance t …
To consider how the CARMELINA study may be interpreted, and the relevance for our clinical practice, we convened as an expert group o …
Anti-Diabetic Agents and Heart Failure - Response to the CARMELINA Study.
Sano M. Sano M. Circ Rep. 2018 Dec 11;1(1):4-7. doi: 10.1253/circrep.CR-18-0011. Circ Rep. 2018. PMID: 33693068 Free PMC article. Review.
Previous cardiovascular outcome trials have mainly focused on type 2 diabetes patients with established cardiovascular disease. In contrast, the CARMELINA study investigated the cardiovascular safety of linagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes and k …
Previous cardiovascular outcome trials have mainly focused on type 2 diabetes patients with established cardiovascular disease. In contrast, …
Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials.
Balasubramanian P, Kernan WN, Sheth KN, Ofstad AP, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi SE. Balasubramanian P, et al. Stroke. 2023 Aug;54(8):2013-2021. doi: 10.1161/STROKEAHA.122.042053. Epub 2023 Jul 14. Stroke. 2023. PMID: 37449424 Free PMC article.
RESULTS: The odds for good versus suboptimal risk factor control in patients with CAD alone was higher than in those with stroke alone across all 3 trials odds ratios (95% CI): CARMELINA, 2.05 (1.67-2.51), EMPA-REG OUTCOME, 2.50 (2.10-2.99), and CAROLINA, 1.63 (1.21-2.20). …
RESULTS: The odds for good versus suboptimal risk factor control in patients with CAD alone was higher than in those with stroke alone acros …
Cardiovascular outcome trials of glucose-lowering medications: an update.
Home P. Home P. Diabetologia. 2019 Mar;62(3):357-369. doi: 10.1007/s00125-018-4801-1. Epub 2019 Jan 3. Diabetologia. 2019. PMID: 30607467 Review.
Three further cardiovascular (CV) outcome studies of glucose-lowering drugs (linagliptin, albiglutide and dapagliflozin) have recently been published, adding to the twelve earlier within-class studies. The linagliptin study (CARMELINA) recruited people with renal disease a …
Three further cardiovascular (CV) outcome studies of glucose-lowering drugs (linagliptin, albiglutide and dapagliflozin) have recently been …
Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA.
Ghosh S, Mukhopadhyay P, Pandey P, Chatterjee P, Pandit K. Ghosh S, et al. Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120973653. doi: 10.1177/1479164120973653. Diab Vasc Dis Res. 2020. PMID: 33213193 Free PMC article.
MATERIALS AND METHODS: We performed an indirect treatment comparison to find the hazard ratio for 3-point MACE, all-cause death, CV death and non-CV death between glimepiride and placebo based on two large CVOTs which established the CV safety of linagliptin (CARMELINA and …
MATERIALS AND METHODS: We performed an indirect treatment comparison to find the hazard ratio for 3-point MACE, all-cause death, CV death an …
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial.
Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A, Schnaidt S, Johansen OE; CARMELINA Investigators. Biessels GJ, et al. Diabetes Care. 2019 Oct;42(10):1930-1938. doi: 10.2337/dc19-0783. Epub 2019 Aug 9. Diabetes Care. 2019. PMID: 31399442 Clinical Trial.
RESEARCH DESIGN AND METHODS: The CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA)-COG substudy was an integral part of CARMELINA (NCT01897532) that randomized participants with cardiorenal disease to linagliptin 5 mg or placebo once …
RESEARCH DESIGN AND METHODS: The CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA)-COG substudy was a …
75 results